PL3377637T3 - Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry - Google Patents

Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry

Info

Publication number
PL3377637T3
PL3377637T3 PL16826873T PL16826873T PL3377637T3 PL 3377637 T3 PL3377637 T3 PL 3377637T3 PL 16826873 T PL16826873 T PL 16826873T PL 16826873 T PL16826873 T PL 16826873T PL 3377637 T3 PL3377637 T3 PL 3377637T3
Authority
PL
Poland
Prior art keywords
wounds
disorders
diseases
skin
compositions
Prior art date
Application number
PL16826873T
Other languages
English (en)
Inventor
Suma Krishnan
Pooja Agarwal
Original Assignee
Krystal Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57822104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3377637(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krystal Biotech, Inc. filed Critical Krystal Biotech, Inc.
Publication of PL3377637T3 publication Critical patent/PL3377637T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11004—Procollagen-lysine 5-dioxygenase (1.14.11.4), i.e. lysine-hydroxylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL16826873T 2016-04-08 2016-12-28 Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry PL3377637T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662320316P 2016-04-08 2016-04-08
EP16826873.8A EP3377637B1 (en) 2016-04-08 2016-12-28 Compositions for use in methods for the treatment of wounds, disorders, and diseases of the skin
PCT/US2016/068974 WO2017176336A1 (en) 2016-04-08 2016-12-28 Compositions and methods for the treatment of wounds, disorders, and diseases of the skin

Publications (1)

Publication Number Publication Date
PL3377637T3 true PL3377637T3 (pl) 2020-09-07

Family

ID=57822104

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16826873T PL3377637T3 (pl) 2016-04-08 2016-12-28 Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry

Country Status (23)

Country Link
US (7) US9877990B2 (pl)
EP (2) EP3712273A1 (pl)
JP (3) JP6970086B2 (pl)
KR (2) KR20250133993A (pl)
CN (1) CN109072255A (pl)
AU (5) AU2016401692B2 (pl)
CA (1) CA3017487A1 (pl)
CL (3) CL2018002814A1 (pl)
CY (1) CY1123024T1 (pl)
DK (1) DK3377637T3 (pl)
ES (1) ES2796488T3 (pl)
HR (1) HRP20200853T1 (pl)
HU (1) HUE049237T2 (pl)
LT (1) LT3377637T (pl)
MX (2) MX394867B (pl)
NZ (1) NZ778381A (pl)
PL (1) PL3377637T3 (pl)
PT (1) PT3377637T (pl)
RS (1) RS60410B1 (pl)
SG (1) SG11201808314QA (pl)
SI (1) SI3377637T1 (pl)
SM (1) SMT202000305T1 (pl)
WO (1) WO2017176336A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3236972T (lt) 2014-12-26 2021-11-10 Emory University Antivirusiniai n4-hidroksicitidino dariniai
PL3377637T3 (pl) * 2016-04-08 2020-09-07 Krystal Biotech, Inc. Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
US10864153B2 (en) * 2016-11-14 2020-12-15 The Regents Of The University Of Michigan Compositions and methods for blocking ultraviolet radiation
EP4382913A3 (en) 2017-01-10 2024-08-14 Precigen, Inc. Modulating expression of polypeptides via new gene switch expression systems
LT3706762T (lt) 2017-12-07 2024-12-27 Emory University N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai
EP3775236A1 (en) 2018-04-12 2021-02-17 Krystal Biotech, LLC Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
MX2020011257A (es) * 2018-04-27 2021-01-15 Krystal Biotech Inc Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
AU2019292580A1 (en) * 2018-06-29 2021-02-04 Krystal Biotech, Inc. Compositions and methods for antibody delivery
AU2019346549B2 (en) * 2018-09-24 2024-09-12 Krystal Biotech, Inc. Compositions and methods for the treatment of Netherton Syndrome
AU2019346461A1 (en) * 2018-09-26 2021-04-15 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
WO2020149395A1 (ja) * 2019-01-18 2020-07-23 国立大学法人大阪大学 栄養障害型表皮水疱症治療薬
SG11202107969SA (en) * 2019-02-08 2021-08-30 Krystal Biotech Inc Compositions and methods for delivering cftr polypeptides
CN114401769A (zh) * 2019-03-27 2022-04-26 菲尼克斯组织修复公司 生产胶原蛋白7组合物的系统和方法
CA3149164A1 (en) 2019-09-03 2021-03-11 Suma Krishnan Compositions and methods for the treatment of congenital ichthyoses
CN112724225B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-6、制法和其药物组合物与用途
WO2021127524A1 (en) 2019-12-20 2021-06-24 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
BR112023020209A2 (pt) 2021-04-02 2023-12-19 Krystal Biotech Inc Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer
MX2024004434A (es) 2021-10-12 2024-07-09 Phoenix Tissue Repair Inc Terapia de reemplazo de proteínas con colágeno 7.
CN117143223B (zh) * 2022-08-23 2024-03-08 山西锦波生物医药股份有限公司 一种生物合成人体结构性材料的制备方法
WO2024214081A1 (en) * 2023-04-13 2024-10-17 Krystal Biotech, Inc. Methods and compositions for the treatment of conditions involving the eye
CN119751645A (zh) * 2024-12-31 2025-04-04 北京华熙荣熙生物技术研究有限公司 一种重组ⅶ型胶原蛋白及其制备方法和应用
CN119685407A (zh) * 2025-02-25 2025-03-25 北京唯源立康生物科技股份有限公司 工程化单纯疱疹病毒载体及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
DE69839243T2 (de) * 1997-04-10 2009-04-30 University Of Southern California, Los Angeles Sich an extrazelluläre matrixbestandteile anbindende modifizierte proteine
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9715085D0 (en) * 1997-07-18 1997-09-24 Jahoda Amanda J Gene therapy vehicle
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
AU4680699A (en) * 1998-06-12 1999-12-30 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
CA2356937A1 (en) * 1998-12-31 2000-07-13 Richard J. Whitley Recombinant herpes simplex virus useful for treating neoplastic disease
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
GB9930418D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
WO2001064747A1 (en) * 2000-03-02 2001-09-07 Isis Innovation Limited Mutations in spink5 responsible for netherton's syndrome and atopic diseases
CA2430341A1 (en) * 2000-11-28 2002-06-06 The University Of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
EP1381280B1 (en) * 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
US20050255085A1 (en) * 2002-03-01 2005-11-17 Yuman Fong Prevention of recurrence and metastasis of cancer
WO2004048938A2 (en) 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2006002394A2 (en) * 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
EP1805213B1 (en) * 2004-10-28 2015-11-18 University of Pittsburgh - Of the Commonwealth System of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
EP1827480B1 (en) * 2004-12-21 2016-11-09 MUSC Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
JP2008528508A (ja) * 2005-01-21 2008-07-31 イントロジェン・セラピューティクス，インコーポレイテッド 標的細胞の治療および予防核酸への持続性の曝露を可能とする局所投与
SI2002003T1 (sl) * 2005-05-27 2016-05-31 Ospedale San Raffaele S.R.L. Genski vektor, ki vsebuje mi-RNA
WO2006130855A2 (en) * 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
US8703703B2 (en) * 2006-12-20 2014-04-22 University Of Central Flordia Research Foundation, Inc. MCPIP as wound therapy
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
WO2008143875A1 (en) * 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
ES2732815T3 (es) * 2009-05-22 2019-11-26 Genocea Biosciences Inc Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria
CN102212559B (zh) 2011-04-14 2014-04-09 郑州威瑞生物技术有限公司 一种重组的hsv扩增子载体及其用途
US9340783B2 (en) * 2011-10-11 2016-05-17 Inserm (Institut National De La Sante Et De La Recherche Medicale Exon skipping therapy for dystrophic epidermolysis bullosa
GB201202561D0 (en) 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
CN104768567B (zh) * 2012-05-18 2017-07-11 奥塔哥创业有限公司 用于伤口愈合的联合治疗和组合物
US9393257B2 (en) * 2013-03-01 2016-07-19 Regents Of The University Of Minnesota TALEN-based gene correction
WO2014153052A2 (en) * 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
KR102382295B1 (ko) * 2013-07-17 2022-04-04 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 효율적인 유전자 전달 적용을 위한 비독성 hsv 벡터 및 이의 생산을 위한 보완 세포
JP6588024B2 (ja) * 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター
RU2714404C2 (ru) * 2014-01-31 2020-02-14 Фэктор Байосайенс Инк. Способы и продукты для получения и доставки нуклеиновых кислот
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
EP3169340B1 (en) * 2014-07-16 2020-09-02 Institut Gustave Roussy Combination of oncolytic virus with immune checkpoint modulators
WO2016049183A1 (en) * 2014-09-24 2016-03-31 Aerpio Therapeutics, Inc. Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
WO2016067628A1 (ja) * 2014-10-31 2016-05-06 京都府公立大学法人 ラミニンによる角膜の新規治療
CA2976376A1 (en) * 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2016191684A1 (en) * 2015-05-28 2016-12-01 Finer Mitchell H Genome editing vectors
RU2762747C2 (ru) * 2015-12-14 2021-12-22 Зе Трастис Оф Зе Юниверсити Оф Пенсильвания Генная терапия офтальмологических нарушений
BR112018015390A2 (pt) * 2016-01-27 2018-12-18 Oncorus, Inc. vetores virais oncolíticos e usos dos mesmos
ES2939644T3 (es) * 2016-03-25 2023-04-25 Periphagen Inc Vectores de HSV de alta transducción
CN109310728B (zh) * 2016-03-25 2022-08-12 普瑞菲根公司 用于递送nt3和治疗cipn的hsv载体
PL3377637T3 (pl) * 2016-04-08 2020-09-07 Krystal Biotech, Inc. Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
EP3775236A1 (en) 2018-04-12 2021-02-17 Krystal Biotech, LLC Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
MX2020011257A (es) 2018-04-27 2021-01-15 Krystal Biotech Inc Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
AU2019292580A1 (en) 2018-06-29 2021-02-04 Krystal Biotech, Inc. Compositions and methods for antibody delivery

Also Published As

Publication number Publication date
EP3377637A1 (en) 2018-09-26
KR20180128016A (ko) 2018-11-30
KR20250133993A (ko) 2025-09-09
US10155016B2 (en) 2018-12-18
MX2022006072A (es) 2022-06-14
AU2019280069A1 (en) 2020-01-16
US20190160122A1 (en) 2019-05-30
CL2021000881A1 (es) 2021-09-10
US20220273737A1 (en) 2022-09-01
LT3377637T (lt) 2020-07-10
DK3377637T3 (da) 2020-05-18
MX394867B (es) 2025-03-24
US20200101123A1 (en) 2020-04-02
AU2022204729B2 (en) 2025-02-06
AU2016401692B2 (en) 2019-10-03
AU2016401692A1 (en) 2018-09-27
AU2025200334B2 (en) 2025-04-17
US20170290866A1 (en) 2017-10-12
RS60410B1 (sr) 2020-07-31
CN109072255A (zh) 2018-12-21
CL2023000743A1 (es) 2023-09-29
SI3377637T1 (sl) 2020-08-31
CA3017487A1 (en) 2017-10-12
SMT202000305T1 (it) 2020-07-08
NZ746213A (en) 2021-08-27
EP3712273A1 (en) 2020-09-23
JP2022023174A (ja) 2022-02-07
HUE049237T2 (hu) 2020-09-28
JP2019513689A (ja) 2019-05-30
JP7480105B2 (ja) 2024-05-09
US20180169160A1 (en) 2018-06-21
AU2025200334A1 (en) 2025-02-20
US11865148B2 (en) 2024-01-09
US10441614B2 (en) 2019-10-15
NZ778381A (en) 2025-07-25
US11185564B2 (en) 2021-11-30
HRP20200853T1 (hr) 2020-08-21
US9877990B2 (en) 2018-01-30
JP6970086B2 (ja) 2021-11-24
US20230414686A1 (en) 2023-12-28
JP2023118838A (ja) 2023-08-25
CL2018002814A1 (es) 2019-02-15
MX2018012135A (es) 2019-03-28
WO2017176336A1 (en) 2017-10-12
ES2796488T3 (es) 2020-11-27
EP3377637B1 (en) 2020-03-18
AU2022204729A1 (en) 2022-07-21
AU2019280069B2 (en) 2022-04-07
CY1123024T1 (el) 2021-10-29
US20230149486A1 (en) 2023-05-18
PT3377637T (pt) 2020-06-17
AU2025204575A1 (en) 2025-07-10
SG11201808314QA (en) 2018-10-30

Similar Documents

Publication Publication Date Title
PL3377637T3 (pl) Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
EP3160493A4 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
PL3405215T3 (pl) Sposoby leczenia choroby danona i innych zaburzeń autofagii
EP3268007A4 (en) Compositions and therapeutic methods for the treatment of complement-associated diseases
ZA201902275B (en) Topical dressing composition for the treatment of damaged skin tissue
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3169321A4 (en) Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health
IL270978B (en) Grape skin for use in the treatment of dysbiosis
SI3722291T1 (sl) Indolinonske spojine in njihova uporaba pri zdravljenju fibrotičnih bolezni
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
SI3307277T1 (sl) Enoverižni oligonukleotidi za uporabo pri zdravljenju motenj kože
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
EP3344233A4 (en) TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF DOXYCLYCLIN AND THEIR USE IN THE TREATMENT OF DOXYCLYCLIN-RELATED ILLNESSES AND SUFFERING
IL246855A0 (en) Materials for use in the treatment of retinitis
SMT202100070T1 (it) Complesso e composizioni per il trattamento di affezioni oculari e cutanee
EP3226865A4 (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
HK1260224A1 (en) Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders
AU2016900442A0 (en) PAK1-blocking esters, preparation, and their use in treatment of cancer and other PAK1-dependent diseases/disorders
HK40007519A (en) Vaccines for use in treating various diseases and disorders
HK40027056A (en) Grape skin for use in the treatment of dysbiosis
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201712742D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases